Towards the end of vaccination with AstraZeneca in Belgium?

Longer time between doses, delays and uncertainties about deliveries, age limit for administering it … the vaccine developed by the University of Oxford and the firm AstraZeneca is no longer really popular with the Belgian vaccination campaign .

In two weeks, there will be no more invitation for a first injection of this vaccine and stocks will be dedicated to the second doses, before being reserved for the Covax program, Sabine Stordeur said on Saturday for the Vaccination Taskforce .

And “disappointments accumulate“for deliveries from Janssen (Johnson & Johson) and AstraZeneca, those from Pfizer / BioNTech and Moderna are stable.

What about Johnson and Johnson?

The delays of Johnson and Johnson could possibly cause a delay of two weeks on the vaccination campaign in summer, or even four to five if the age limit (of 41 years and over) is maintained after the current risk / benefit analysis. Half of adults will have received at least one dose of the vaccine next week and the milestone of 80% of people “with comorbidities“vaccinated should also be crossed in the coming days.

Read more:  "For banks we already represent a sector of high financial risk"

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.